Latest News and Press Releases

TOS-358 is a covalent, pan-mutant, a-selective PI3K inhibitor designed to address key limitations of existing PI3Ka therapies which include limited mutation coverage and poor tolerability First...

TOS-358 is a covalent, pan-mutant, α-specific PI3K inhibitor designed to address key limitations of existing PI3Kα therapies which include limited mutation coverage and poor tolerability Data will...

First-in-class, covalent, oral small molecule inhibitor targeting IRF5 IRF5 is a genetically validated driver of autoimmune diseases, including systemic lupus erythematosus, Sjögren’s disease, and...

Oral presentation of Ph 1a clinical data highlights potential best-in-class drug profile in heavily pretreated patients with PI3Ka-mutant metastatic breast cancer and other solid tumors Overall,...

Oral presentation to highlight updated Phase 1 monotherapy safety and efficacy data for TOS-358, a covalent PI3Ka inhibitor Data will include efficacy and safety in heavily pretreated patients with...

15th Jan 2026 10:30 AM - 10:55 AM PSTElizabethan D - Private Company Track; Westin St. Francis Hotel, San Francisco, CA EMERYVILLE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Totus Medicines, a...

EMERYVILLE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools,...

Successfully completed a Phase 1 dose-escalation study demonstrating pan-mutant clinical activity, 95% target engagement and no grade 3 or 4 toxicities at doses as low as 5 mg BID Initiating an...

EMERYVILLE, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools,...